AEON Biopharma (NASDAQ:AEON – Get Free Report) and Silverback Therapeutics (NASDAQ:SBTX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.
Profitability
This table compares AEON Biopharma and Silverback Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AEON Biopharma | N/A | N/A | -994.63% |
| Silverback Therapeutics | N/A | -29.62% | -28.20% |
Valuation & Earnings
This table compares AEON Biopharma and Silverback Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AEON Biopharma | N/A | N/A | -$36.63 million | $5.04 | 0.20 |
| Silverback Therapeutics | N/A | N/A | -$89.48 million | ($2.42) | -3.64 |
Silverback Therapeutics is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for AEON Biopharma and Silverback Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AEON Biopharma | 0 | 1 | 1 | 1 | 3.00 |
| Silverback Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
Volatility & Risk
AEON Biopharma has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, Silverback Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500.
Institutional & Insider Ownership
22.8% of AEON Biopharma shares are owned by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are owned by institutional investors. 0.9% of AEON Biopharma shares are owned by insiders. Comparatively, 34.4% of Silverback Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
AEON Biopharma beats Silverback Therapeutics on 8 of the 11 factors compared between the two stocks.
About AEON Biopharma
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.
About Silverback Therapeutics
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Receive News & Ratings for AEON Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEON Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
